Dependence potential of zopiclone studied in monkeys.
In gross behavioral observation the minimum effective dose of zopiclone was intravenously 0.06-0.25 mg/kg and intragastrically 1-4 mg/kg in rhesus monkeys. Zopiclone suppressed barbital withdrawal signs of rhesus monkeys at a single dose of 16 mg/kg or more. The suppressing effect of zopiclone 32 mg/kg i.g. was comparable to diazepam 8 mg/kg. Crab-eating monkeys treated with zopiclone at doses up to 32 mg/kg twice daily for up to 8 weeks manifested intermediate-grade signs upon withdrawal (i.e., less severe than after treatment with diazepam and similar to nitrazepam). Zopiclone was self-administered by rhesus monkeys relatively frequently by the intravenous route; the infrequent intragastric rate was similar to or slightly higher than with diazepam.
D000284:Administration, Oral; D000818:Animals; D053961:Azabicyclo Compounds; D001462:Barbital / Q000494:pharmacology; D003975:Diazepam / Q000494:pharmacology; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D007263:Infusions, Parenteral; D008252:Macaca fascicularis; D008253:Macaca mulatta; D008297:Male; D009567:Nitrazepam / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology*; D012646:Self Administration; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D019966:Substance-Related Disorders / Q000209:etiology*
D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; C515050:zopiclone; D001462:Barbital; D009567:Nitrazepam; D003975:Diazepam